Biocon leads India push into weight loss drugs as patents lapse

Biocon Ltd., headquartered in Bengaluru, is shifting its focus towards anti-obesity therapies as patents for its blockbuster medications begin to expire. This move comes in response to the anticipated surge in generic supply for the market, projected to reach $100 billion by 2030. The company has scored an early win among its peers with the UK approval for the first generic version of liraglutide injectible.